The terms “process-specific” and “generic” are commonly used in scientific publications and regulatory guidelines in reference to host cell protein (HCP) analysis of recombinant biopharmaceuticals.
In a typical bioprocessing run, the engineered cells produce a drug—but that’s not all. They also express and release host cell proteins (HCPs). Depending on the specific HCP and its concentration, it ...